Episode #6
The PBS Update August 2026
Send us Fan Mail PBS listings can radically reshape practice and the August changes are all about precision. Rachael Babin from the Oncology Network sits down with Professor Craig Underhill to translate the latest Australian Pharmaceutical Benefits Scheme (PBS) oncology and haematology listings into what clinicians actually need: who’s eligible, what the key trials show and what to watch for once the script is written. We start with vorasidenib , newly listed for IDH mutant astrocytomas and oligodendrogliomas. Alongside a powerful public advocacy story, we unpack the INDIGO phase 3 data and why a clear progression-free survival gain matters for patients facing long treatment journeys. We also get practical about toxicity, including fatigue and liver function abnormalities, and the reality that chronic low-grade side effects still require close monitoring and supportive care to keep people well on therapy. Next, we move to selpercatinib for RET-mutated medullary thyroid cancer, a rare disease where “getting the target right” can be transformative. Craig talks us through the LIBRETTO-531 results, what “PFS not reached” signals, and why tolerability and discontinuation rates matter just as much as headline efficacy. We then cover tafasitamab (anti-CD19) added to rituximab and lenalidomide for relapsed or refractory follicular lymphoma, including day unit visit burden, neutropenia risk and the size of the benefit reported. To close, we ask the bigger question: as targeted therapy and tumour-agnostic approvals increase, are we heading toward mutation specialists rather than tumour-type silos? If this helped you keep up with PBS oncology and haematology updates, please subscribe, share it with a colleague and leave a review so more clinicians can find us. Visit the Show Notes for links to the papers and other materials related to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes . Proudly produced by The Oncology Network
